Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic

Gagneux-Brunon et al., Trials, doi:10.1186/s13063-021-05329-y, NCT04328285
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
118 participant HCQ prophylaxis RCT with results not reported over 2 years after completion.
38 HCQ RCTs have results missing long after expected1-38
The trials report a total of 25,399 patients, with 12 trials having actual enrollment of 8,139, and the remainder estimated.
Gagneux-Brunon et al., 30 Mar 2022, Double Blind Randomized Controlled Trial, placebo-controlled, France, peer-reviewed, study period 14 April, 2020 - 30 March, 2022, trial NCT04328285 (history). Contact: elisabeth.botelho-nevers@chu-saint-etienne.fr (corresponding author), Arnauld.Garcin@chu-st-etienne.fr, nathalie.jolly@pasteur.fr.
This PaperHCQAll
Abstract: Gagneux-Brunon et al. Trials (2021) 22:373 https://doi.org/10.1186/s13063-021-05329-y LETTER Open Access Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic Amandine Gagneux-Brunon1,2, Clémentine Schilte3, Arnauld Garcin4, Nathalie Jolly3, Muriel Vray5, Laura Schaeffer5, Xavier Duval6, Bruno Hoen7 and Elisabeth Botelho-Nevers1,2* Keywords: Pre-exposure chemoprophylaxis trial, SARS-CoV-2 infection, Healthcare workers, Acceptability, Hydroxychloroquine Healthcare workers (HCWs) have been over-represented among people infected with Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). In France, between March 1 and November 2, 2020, SARS-CoV-2 infection was diagnosed in more than 44,000 HCWs and killed 17 [1]. In the USA, HCWs accounted for around 20% of the confirmed cases of SARS-CoV-2 infections by April 2020 [2]. Protection of HCWs rapidly became a crucial challenge during the COVID-19 pandemics [3]. Pre- and post-exposure chemoprophylaxis was considered to be used in addition to personal protective equipment. More than 50 clinical trials aiming to assess chloroquine or hydroxychloroquine (HCQ) in HCWs and/or household contacts of COVID-19 cases have been registered worldwide with ClinicalTrials.gov. In France in April 2020, a multi-center randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a 2-month pre-exposure prophylaxis with HCQ in 600 HCWs exposed to COVID-19 patients was started [4]. This trial was funded by the French hospital program for clinical research (PHRC) and sponsored by * Correspondence: elisabeth.botelho-nevers@chu-saint-etienne.fr 1 Department of Infectious diseases, University Hospital of Saint-Etienne, Saint-Etienne, 42055, France 2 CIC-1408 Vaccinology, INSERM, University Hospital of Saint-Etienne, Saint-Etienne, 42055, France Full list of author information is available at the end of the article the University Hospital of Saint-Etienne in collaboration with Institut Pasteur in Paris. For each participant, six visits at the investigation center, one weekly electrocardiogram, 5 blood samplings, and 4 nasopharyngeal swabs for SARS-CoV-2 RT-PCR were scheduled. Before the trial started, we conducted an anonymous online survey in ten of the investigation centers to evaluate the acceptability of the trial among HCWs, whether they worked in a hospital, an ambulatory setting, or a long-term care facility. Eight hundred and seventy-one HCWs completed the survey. Among respondents, 695 (79.8%) reported they were interested in participating in the trial. Intention to participate was not influenced by age or working place. Among the 695 potential volunteers, 430 (61.9%) were under 45 years of age and only 126 (18.1%) reported a significant comorbidity. The main reasons for declining participation in the study were the following: (1) fears about HCQ side effects in 121 of the 176 decliners (68.8%), (2) the perception that the individual risk of severe COVID-19 was low in 36 (20.5%), (3) the constraints resulting from the number of study visits in 29 (16.5%), and (4) the burden of nasopharyngeal swabs for SARS-CoV-2 RT-PCR in 25 (14.2%). Six hundred and ninety-five respondents reported being interested in participating in the chemoprophylaxis trial, and 117 were actually enrolled by May 27, 2020. In the first center where the trial was started, 342 HCWs reported being © The Author(s)...
{ 'indexed': {'date-parts': [[2022, 12, 4]], 'date-time': '2022-12-04T05:27:24Z', 'timestamp': 1670131644647}, 'reference-count': 6, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 5, 30]], 'date-time': '2021-05-30T00:00:00Z', 'timestamp': 1622332800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2021, 5, 30]], 'date-time': '2021-05-30T00:00:00Z', 'timestamp': 1622332800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'DOI': '10.13039/501100006022', 'name': 'Ministère des Affaires Sociales, de la Santé et des Droits des Femmes', 'doi-asserted-by': 'publisher', 'award': ['SERI-COVID-I 2020-0355']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 12]]}, 'DOI': '10.1186/s13063-021-05329-y', 'type': 'journal-article', 'created': {'date-parts': [[2021, 5, 30]], 'date-time': '2021-05-30T19:21:37Z', 'timestamp': 1622402497000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French ' 'healthcare workers during the first wave of COVID-19 pandemic', 'prefix': '10.1186', 'volume': '22', 'author': [ {'given': 'Amandine', 'family': 'Gagneux-Brunon', 'sequence': 'first', 'affiliation': []}, {'given': 'Clémentine', 'family': 'Schilte', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arnauld', 'family': 'Garcin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nathalie', 'family': 'Jolly', 'sequence': 'additional', 'affiliation': []}, {'given': 'Muriel', 'family': 'Vray', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Schaeffer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xavier', 'family': 'Duval', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno', 'family': 'Hoen', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2773-7750', 'authenticated-orcid': False, 'given': 'Elisabeth', 'family': 'Botelho-Nevers', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 5, 30]]}, 'reference': [ { 'key': '5329_CR1', 'unstructured': 'Recensement national des cas de COVID-19 chez les professionnels en ' 'établissements de santé [Internet]. [cited 2020 Nov 9]. Available from: ' 'https://www.santepubliquefrance.fr/etudes-et-enquetes/recensement-national-des-cas-de-covid-19-chez-les-professionnels-en-etablissements-de-sante.'}, { 'issue': '15', 'key': '5329_CR2', 'doi-asserted-by': 'publisher', 'first-page': '477', 'DOI': '10.15585/mmwr.mm6915e6', 'volume': '69', 'author': 'CDC COVID-19 Response Team', 'year': '2020', 'unstructured': 'CDC COVID-19 Response Team. Characteristics of health care personnel ' 'with COVID-19 - United States, February 12-April 9, 2020. MMWR Morb ' 'Mortal Wkly Rep. 2020;69(15):477–81.', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'issue': '10228', 'key': '5329_CR3', 'doi-asserted-by': 'publisher', 'first-page': '922', 'DOI': '10.1016/S0140-6736(20)30644-9', 'volume': '395', 'author': 'The Lancet', 'year': '2020', 'unstructured': 'The Lancet. COVID-19: protecting health-care workers. Lancet. ' '2020;395(10228):922. https://doi.org/10.1016/S0140-6736(20)30644-9.', 'journal-title': 'Lancet.'}, { 'key': '5329_CR4', 'unstructured': 'Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in exposed ' 'healthcare workers - full text view - ClinicalTrials.gov [Internet]. ' '[cited 2020 Jul 3]. Available from: ' 'https://clinicaltrials.gov/ct2/show/NCT04328285.'}, { 'key': '5329_CR5', 'doi-asserted-by': 'crossref', 'unstructured': 'Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. ' 'Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure ' 'SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical ' 'Trial. JAMA Intern Med. 2021;181(2):195-202.', 'DOI': '10.1001/jamainternmed.2020.6319'}, { 'key': '5329_CR6', 'doi-asserted-by': 'crossref', 'unstructured': 'Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ' 'ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 ' 'in healthcare workers: a randomized trial. Clin Infect Dis. ' '2020:ciaa1571.', 'DOI': '10.1101/2020.09.18.20197327'}], 'container-title': 'Trials', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-021-05329-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s13063-021-05329-y/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-021-05329-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 5, 30]], 'date-time': '2021-05-30T19:23:28Z', 'timestamp': 1622402608000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05329-y'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 5, 30]]}, 'references-count': 6, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['5329'], 'URL': 'http://dx.doi.org/10.1186/s13063-021-05329-y', 'relation': {}, 'ISSN': ['1745-6215'], 'subject': ['Pharmacology (medical)', 'Medicine (miscellaneous)'], 'container-title-short': 'Trials', 'published': {'date-parts': [[2021, 5, 30]]}, 'assertion': [ { 'value': '18 November 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '18 May 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 May 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Acceptability study reported here, performed in link to the trial COVIDAXIS ' '(NCT04328285) was approved by the Ethics committee of University Hospital of ' 'Saint-Etienne (IRBN822020/CHUSTE.). Here, we do not report results of COVIDAXIS ' 'trial (trial that was approved by CPPIDF1-2020-ND47).', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare that they have no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '373'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit